Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect


Dr.Reddy’s gearing up with Covid portfolio: Deepak Sapra, CEO of API & Services, speaks to India Today

Dr Reddy’s Laboratories is strengthening its efforts to bring both curative and preventive products (drugs and vaccines) to fight Covid-19. With the launch of Redyx (Remdesivir) and Avigan (Favipiravir), Dr.Reddy’s has reaffirmed its commitment to bring critical medicines for patients suffering from Covid-19.

In addition to the medicines, Dr.Reddy’s has also received 1.5 lakh doses of Sputnik V vaccine from Russia on May 1, 2021 and is currently in the process of rolling out the vaccine in India. The company expects a steady ramp up over May and June and plan to vaccinate 125 million people in the next 8-12 months across the country. Dr Reddy’s is also working with RDIF to launch in a few other markets, particularly in emerging markets.

Deepak Sapra, CEO - API and Services, spoke to India today about Sputnik V vaccine’s clearance, soft launch, production in India, pricing and the road ahead for Sputnik V light.

Click here to view Deepak Sapra exclusive interview with India Today.

Contact Us

Please fill in the following form and we'll get back to you shortly.

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit